On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first COVID-19 diagnostic test that detected chemical compounds in breath samples associated with a SARS-CoV-2 infection.

The test can be performed in environments where the patient specimen is both collected and analyzed, such as doctorﾒs offices, hospitals and mobile testing sites, using an instrument about the size of a piece of carry-on luggage. The test is performed by a qualified, trained operator under the supervision of a health care provider licensed or authorized by state law to prescribe tests and can provide results in less than three minutes.